Skip to main content

Advertisement

SpringerLink
Log in

Survival and prognostic factors in Malaysian acute myeloid leukemia patients after allogeneic haematopoietic stem cell transplantation

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Studies of survival outcomes in acute myeloid leukemia (AML) patients treated with allogeneic haematopoietic stem cell transplantation (HSCT) are essential for planning patient care. The objectives of the present study were to determine overall survival (OS) and disease-free survival (DFS) in AML patients treated with allogeneic HSCT, and to identify prognostic factors associated with poor outcome. This study was conducted retrospectively, using data from the Blood and Bone Marrow Transplant, National Transplant Registry, Malaysia. All cases of AML treated with allogeneic HSCT registered at the registry between 1st January 1987 and 31st December 2010 were included in the study. A total of 300 patients were included for final analysis. The Kaplan–Meier method and Cox proportional hazard regression were used for statistical analysis. The overall 10-year OS and DFS for Malaysian AML patients after allogeneic HSCT were 63 and 67 %, respectively. Donor gender, marrow status, and conditioning intensity were identified as important prognostic factors for overall survival, whereas the significant prognostic factors for disease-free survival were ethnic group, donor gender, marrow status, and conditioning intensity. In conclusion, the survival outcomes for Malaysian AML patients treated with allogeneic HSCT were good, and this treatment should be considered the standard therapeutic approach for suitable candidates.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Hooi LS, Mansor LY, editors. Fifth report of the National Transplant Registry Malaysia 2008. Kuala Lumpur: National Transplant Registry; 2010.

    Google Scholar 

  2. Gan GG, Teh A, Chan LL, Cheong SK, Chang KM, Ibrahim HM. Bone marrow and stem cell transplantation: Malaysian experience. Bone Marrow Transplant. 2008;42:S103–5.

    Article  PubMed  Google Scholar 

  3. Moore J, Nivison-Smith I, Goh K, Ma D, Bradstock K, Szer J, et al. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant. 2007;13(5):601–7.

    Article  PubMed  Google Scholar 

  4. Atsuta Y, Suzuki R, Nagamura-Inoue T, Taniguchi S, Takahashi S, Kai S, et al. Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia. Blood. 2009;113(8):1631–8.

    Article  PubMed  Google Scholar 

  5. Walter RB, Pagel JM, Gooley TA, Petersdorf EW, Sorror ML, Woolfrey AE, et al. Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission. Leukemia. 2010;24(7):1276–82.

    Article  PubMed  CAS  Google Scholar 

  6. Nivison-Smith I, Dodds AJ, Dunckley H, Ma DDF, Moore JJ, Simpson JM et al. Increased activity and improved outcome in unrelated donor haemopoietic cell transplants for acute myeloid leukaemia in Australia, 1992–2005. Intern Med J 2011; 41(1a):27–34.

    Google Scholar 

  7. Michallet M, Thomas X, Vernant J, Kuentz M, Socie G, Esperou-Bourdeau H, et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM). Bone Marrow Transplant. 2000;26(11):1157.

    Article  PubMed  CAS  Google Scholar 

  8. Greinix HT, Nachbaur D, Krieger O, Eibl M, Knobl P, Kalhs P, et al. Factors affecting long-term outcome after allogeneic haematopoietic stem cell transplantation for acute myelogenous leukaemia: a retrospective study of 172 adult patients reported to the Austrian Stem Cell Transplantation Registry. Br J Haematol. 2002;117(4):914–23.

    Article  PubMed  Google Scholar 

  9. Cornelissen JJ, van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood. 2007;109(9):3658–66.

    Article  PubMed  CAS  Google Scholar 

  10. Eapen M, Rubinstein P, Zhang MJ, Stevens C, Kurtzberg J, Scaradavou A, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet. 2007;369(9577):1947–54.

    Article  PubMed  Google Scholar 

  11. Ringden O, Labopin M, Ehninger G, Niederwieser D, Olsson R, Basara N, et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol. 2009;27(27):4570–7.

    Article  PubMed  Google Scholar 

  12. Mielcarek M, Gooley T, Martin PJ, Chauncey TR, Young BA, Storb R, et al. Effects of race after stem cell transplantation. Biol Blood Marrow Transplant. 2005;11(3):231–9.

    Article  PubMed  Google Scholar 

  13. Oh H, Loberiza FR Jr, Zhang M, Ringden O, Akiyama H, Asai T, et al. Comparison of graft-vs-host disease and survival after HLA identical sibling bone marrow transplantation in different ethnic populations. Blood. 2005;105:1408–16.

    Article  PubMed  CAS  Google Scholar 

  14. Karanth M, Begum G, Cook M, Lawson S, Porter C, Lister N, et al. Increased acute GvHD and higher transplant-related mortality in non-caucasians undergoing standard sibling allogeneic stem cell transplantation. Bone Marrow Transplant. 2006;37:419–23.

    Article  PubMed  CAS  Google Scholar 

  15. Yakoub-Agha I, Mesnil F, Kuentz M, Boiron JM, Ifrah N, Milpied N, et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol. 2006;24(36):5695–702.

    Article  PubMed  Google Scholar 

  16. Weisdorf D, Hakke R, Blazar B, Miller W, McGlave P, Ramsay N, et al. Risk factors for acute graft-versus-host-disease in histocompatible bone marrow transplantation. Transplantation. 1991;51:1197–203.

    Article  PubMed  CAS  Google Scholar 

  17. Nash RA, Pepe MS, Storb R, Longton G, Pettinger M, Anasetti C, et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood. 1992;80(7):1838–45.

    PubMed  CAS  Google Scholar 

  18. Kollman C, Howe CWS, Anasetti C, Antin JH, Davies SM, Filipovich AH, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001;98(7):2043–51.

    Article  PubMed  CAS  Google Scholar 

  19. Aoudjhane M, Labopin M, Gorin NC, Shimoni A, Ruutu T, Kolb HJ, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia. 2005;19(12):2304–12.

    Article  PubMed  CAS  Google Scholar 

  20. Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D, et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood. 2006;108(3):1092–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We would like to thank the National Transplant Registry, Malaysia, for providing the data.

Conflict of interest

The authors declared no financial interests.

Author information

Authors and Affiliations

  1. Regenerative Medicine Cluster, Advanced Medical & Dental Institute, Universiti Sains Malaysia, Bertam, 13200, Kepala Batas, Pulau Pinang, Malaysia

    Ernest Mangantig

  2. Unit of Biostatistics & Research Methodology, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, 16150, Kubang Kerian, Kelantan, Malaysia

    Nyi Nyi Naing & Bachok Norsa’adah

  3. Medical Department, Hospital Universiti Sains Malaysia, Jalan Raja Perempuan Zainab II, 16150, Kubang Kerian, Kelantan, Malaysia

    Husin Azlan

Authors
  1. Ernest Mangantig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nyi Nyi Naing
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bachok Norsa’adah
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Husin Azlan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ernest Mangantig.

About this article

Cite this article

Mangantig, E., Naing, N.N., Norsa’adah, B. et al. Survival and prognostic factors in Malaysian acute myeloid leukemia patients after allogeneic haematopoietic stem cell transplantation. Int J Hematol 98, 197–205 (2013). https://doi.org/10.1007/s12185-013-1373-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-013-1373-1

Keywords

Search

Navigation